GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (LTS:0MGB) » Definitions » EV-to-FCF

Genmab AS (LTS:0MGB) EV-to-FCF : 9.35 (As of Mar. 15, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Genmab AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genmab AS's Enterprise Value is kr69,788 Mil. Genmab AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr7,467 Mil. Therefore, Genmab AS's EV-to-FCF for today is 9.35.

The historical rank and industry rank for Genmab AS's EV-to-FCF or its related term are showing as below:

LTS:0MGB' s EV-to-FCF Range Over the Past 10 Years
Min: -1007.34   Med: 59.72   Max: 7818.73
Current: 9.35

During the past 13 years, the highest EV-to-FCF of Genmab AS was 7818.73. The lowest was -1007.34. And the median was 59.72.

LTS:0MGB's EV-to-FCF is ranked worse than
55.98% of 418 companies
in the Biotechnology industry
Industry Median: 3.73 vs LTS:0MGB: 9.35

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-15), Genmab AS's stock price is kr1423.50. Genmab AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr121.330. Therefore, Genmab AS's PE Ratio (TTM) for today is 11.73.


Genmab AS EV-to-FCF Historical Data

The historical data trend for Genmab AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS EV-to-FCF Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.73 77.90 47.44 16.19 10.01

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.19 20.00 14.74 13.19 10.01

Competitive Comparison of Genmab AS's EV-to-FCF

For the Biotechnology subindustry, Genmab AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Genmab AS's EV-to-FCF falls into.



Genmab AS EV-to-FCF Calculation

Genmab AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=69788.035/7467
=9.35

Genmab AS's current Enterprise Value is kr69,788 Mil.
Genmab AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr7,467 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (LTS:0MGB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Genmab AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1423.50/121.330
=11.73

Genmab AS's share price for today is kr1423.50.
Genmab AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr121.330.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Genmab AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Genmab AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines